未登录

Y

Yinnan Meng

University of Hong Kong

H指数:10

被引数:265

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Differential survival impact of acetaminophen and non-steroidal anti-inflammatory drugs on NSCLC patients undergoing immune checkpoint inhibitor therapy: a region-wide cohort study in Hong Kong, China

对接受免疫检查点抑制剂治疗的NSCLC患者，乙酰氨基酚与非甾体抗炎药差异化生存影响的区域队列研究：中国香港地区

Journal of the National Cancer Center

IF9.4

2026-02-150

OAAI

DNA Repair Genetics and the Risk of Radiation Pneumonitis in Patients With Lung Cancer: A Systematic Review and Meta-analysis

CLINICAL ONCOLOGY

IF3

2024-07-011

PRE

Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiation Therapy in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2024-02-0110

PRE

Effect of radiation fractionation on IDO1 via the NF-κB/COX2 axis in non-small cell lung cancer

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2023-11-010

OAAI

CT-based radiomics nomogram may predict who can benefit from adaptive radiotherapy in patients with local advanced-NSCLC patients

基于CT的影像组学列线图可以预测谁可以从局部晚期NSCLC患者的适应性放疗中受益

RADIOTHERAPY AND ONCOLOGY

IF5.3

2023-06-014

PRE

Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR-Mutation-Positive Lung Cancer with EFGR-TKI Treatment: A Prospective, Single Arm, Phase II Study

IF3.4

2022-11-222

OAAI

The critical components for effective adaptive radiotherapy in patients with unresectable non-small-cell lung cancer: who, when and how

不可切除的非小细胞肺癌患者有效自适应放疗的关键组成部分: 谁，何时以及如何

FUTURE ONCOLOGY

IF2.6

2022-10-034

OA

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-09-156

OAAI

Enhanced CT-Based Radiomics to Predict Micropapillary Pattern Within Lung Invasive Adenocarcinoma

基于增强CT的影像组学预测肺浸润性腺癌内的微乳头状模式

FRONTIERS IN ONCOLOGY

IF3.3

2021-08-2715

OAAI

Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling

FRONTIERS IN ONCOLOGY

IF3.3

2021-06-0816

OAAI

Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?

RADIOTHERAPY AND ONCOLOGY

IF5.3

2021-05-0117

OAAI

FLVCR1 Predicts Poor Prognosis and Promotes Malignant Phenotype in Esophageal Squamous Cell Carcinoma via Upregulating CSE1L

FRONTIERS IN ONCOLOGY

IF3.3

2021-03-255

OAAI

GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer

GBP1促进吲哚胺2，3-双加氧酶胞外分泌促进肺癌恶性进展

FRONTIERS IN IMMUNOLOGY

IF5.9

2021-01-2022

OAAI

Intermediate Dose-Volume Parameters, Not Low-Dose Bath, Is Superior to Predict Radiation Pneumonitis for Lung Cancer Treated With Intensity-Modulated Radiotherapy

FRONTIERS IN ONCOLOGY

IF3.3

2020-10-1512

OAAI

Excluding PTV from lung volume may better predict radiation pneumonitis for intensity modulated radiation therapy in lung cancer patients

RADIATION ONCOLOGY

IF3.2

2019-01-1415

OAAI